Akoya Biosciences and NeraCare Enter into an Exclusive Agreement to Enable Personalized Therapy Selection for Early-Stage Melanoma Patients

May 9, 2024

https://www.globenewswire.com/news-release/2024/05/09/2878692/0/en/Akoya-Biosciences-and-NeraCare-Enter-into-an-Exclusive-Agreement-to-Enable-Personalized-Therapy-Selection-for-Early-Stage-Melanoma-Patients.html

MARLBOROUGH, Mass. and FRANKFURT, Germany, May 09, 2024 (GLOBE NEWSWIRE) — Akoya Biosciences, Inc. (Nasdaq:AKYA), The Spatial Biology Company®, and NeraCare, a leading developer of laboratory tests for the prognosis of melanoma patients, announced an exclusive agreement today under which the parties will develop market opportunities for combining Akoya’s PhenoImager HT platform and NeraCare’s Immunoprint assay for patient stratification and therapy selection in early-stage melanoma patients.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.